TauRx Pharmaceuticals

What TauRx Pharmaceuticals does

TauRx Pharmaceuticals is a privately held life sciences company founded in 2002 in Singapore, developing disease-modifying treatments and diagnostic tools for neurodegenerative diseases, with a primary focus on Alzheimer's disease and frontotemporal dementia. The company's core technology is a proprietary Tau Aggregation Inhibitor (TAI) platform based on hydromethylthionine mesylate (HMTM), an oral small-molecule compound discovered through research initiated by co-founder Prof Claude Wischik in 1988 and 1996. HMTM targets tau tangle pathology in the brain via a mechanism distinct from anti-amyloid approaches, and is administered as a film-coated tablet designed for early intervention in mild cognitive impairment (MCI) and mild-to-moderate Alzheimer's disease.

The company has completed Phase III clinical trials (LUCIDITY) involving approximately 3,000 patients across North America and Europe, demonstrating pharmacological activity on clinical decline and brain atrophy. In 2022, TauRx submitted HMTM to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for approval and received an Innovation Passport acknowledging innovative potential; a confirmatory study was published in the Journal of Prevention of Alzheimer's Disease in 2024. The company is incorporated in Scotland (TauRx Therapeutics Management Limited, Registered Number SC531195) and operates from headquarters in Singapore with a UK operational base in Aberdeen. It has a leadership team led by Prof Claude Wischik (Co-Founder, Chairman and CEO), Dr Glenn Corr (COO/CBO), Prof Bjoern Schelter (Chief Analytics Officer), Prof John Storey (CTO), and Dr Richard Stefanacci (CMO).

TauRx is pre-commercial and pre-revenue, with no products currently generating sales. The planned business model upon regulatory approval is prescription pharmaceutical sales through healthcare systems, hospitals, and pharmacies, supported by the company's joint venture GT Diagnostics (with Genting Berhad) which develops digital diagnostic tools for early dementia detection and progression monitoring. The company has been funded through multiple private rounds totaling over $377 million since 2012, with Dundee Corporation holding approximately 1,007,008 shares at US$125/share as of 2024.

Name

TauRx Pharmaceuticals

Legal name

TauRx Therapeutics Management Limited

Website

http://taurx.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

501–1,000 employees

Short description

TauRx Pharmaceuticals is a Singapore-headquartered, privately held life sciences company developing HMTM, an oral tau aggregation inhibitor for Alzheimer's disease and frontotemporal dementia, currently awaiting MHRA approval. It serves MCI and Alzheimer's patients via pharmaceutical sales and operates a diagnostic joint venture.

Ownership category

akta.pro rank

Product category

Alzheimer's Disease Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Tau aggregation inhibitors
• Alzheimer's disease therapeutics
• Neurodegenerative disease treatment
• Clinical-stage pharmaceuticals
• Dementia drug development

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. HMTM Pharmaceutical Sales: Pre-commercial stage. HMTM has been submitted for regulatory approval to MHRA as a tablet to treat MCI and mild to moderate Alzheimer's disease. Once approved, the company will generate revenue through prescription pharmaceutical sales. The company states HMTM has a strong safety profile not requiring expensive tests or scans for routine monitoring, potentially offering cost advantages.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

TauRx Pharmaceuticals is developing hydromethylthionine mesylate (HMTM), an oral, film-coated tablet that acts as a Tau Aggregation Inhibitor (TAI) targeting tau pathology in the brain to modify disease progression in mild cognitive impairment (MCI) and mild-to-moderate Alzheimer's disease. The compound has completed Phase III clinical trials (LUCIDITY) and has been submitted to the UK's MHRA for regulatory approval as the company's first commercial product. Through its GT Diagnostics joint venture, the company also develops digital tools for early dementia diagnosis and progression monitoring.

Product overview

TauRx Pharmaceuticals is a life sciences company focused on developing treatments for Alzheimer's disease and other neurodegenerative diseases caused by protein aggregation. The company's core product is HMTM (hydromethylthionine mesylate), an oral tau aggregation inhibitor tablet that has completed Phase III clinical trials (LUCIDITY) and was submitted for regulatory approval to the UK's MHRA in 2024. Complementary to its treatment pipeline, TauRx operates through a joint venture GT Diagnostics focused on digital diagnostic tools for dementia. The company was founded in 2002 in Singapore with roots in both Singapore and the United Kingdom.

Differentiator

Problem solved

Functional benefit

Brands

• HMTM (Hydromethylthionine Mesylate): Oral tau aggregation inhibitor tablet for treatment of mild cognitive impairment and mild to moderate Alzheimer's disease
• GT Diagnostics

Products and services

• HMTM (Hydromethylthionine Mesylate) Oral, film-coated tablet formulated as a Tau Aggregation Inhibitor (TAI) for early intervention in Alzheimer's disease to modify the underlying disease process and slow progression. Designed to dissolve tau tangles in the brain through a mechanism distinct from anti-amyloid therapies, with a strong safety profile requiring minimal routine monitoring (no expensive scans or tests). Targeted at patients with mild cognitive impairment and mild-to-moderate Alzheimer's disease, prescribed by neurologists, geriatricians, and primary care physicians.

Quantifiable outcome

• Phase III trials demonstrated pharmacological activity on clinical decline and brain atrophy in Alzheimer's disease and frontotemporal dementia
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• GT Diagnostics (Joint Venture with Genting Berhad)coreStrategic or Co-development PartnerTauRx collaborates with Genting Berhad to create the joint venture GT Diagnostics, which aims to change the diagnostic landscape of dementia by developing tools for early diagnosis and monitoring progression. Focus on using digital tools to address bottlenecks in the diagnostic pathway, aiding clinicians to streamline dementia diagnosis. This is complementary to TauRx's research expertise focused on developing treatments.

Scale indicators4 records

Recent moves3 records

Expansion highlights6 records

Direct peers

• Cassava Sciences: Late-stage clinical biopharma focused on a disease-modifying oral therapy (simufilam) for Alzheimer's disease, directly comparable in target indication, modality (oral small molecule), and pre-commercial regulatory stage.
• AC Immune: Clinical-stage biopharma developing therapeutics and diagnostics targeting tau and other misfolded proteins in Alzheimer's and neurodegeneration, comparable in tau-pathology focus and integrated diagnostic-therapeutic strategy.
• Anavex Life Sciences: Clinical-stage biopharma developing small-molecule therapies for Alzheimer's disease and other neurodegenerative conditions, with a similar late-stage CNS profile and similar go-to-market through regulatory submissions in Alzheimer's.
• Axon Neuroscience: Tau-pathology-focused clinical-stage biopharma developing vaccines and therapeutics for Alzheimer's and frontotemporal dementia, directly comparable in tau-targeting approach and neurodegenerative focus.
• Cognition Therapeutics: Clinical-stage CNS biopharma developing small-molecule therapies for Alzheimer's disease, sharing a similar late-stage private/early-public profile and oral small-molecule CNS modality.

Broad incumbents

• Eli Lilly: Large pharma that developed and launched Kisunla (donanemab) for early symptomatic Alzheimer's disease, a direct therapeutic competitor to HMTM in the same target population.
• Eisai: Large Japanese pharmaceutical company co-developing and commercializing Leqembi (lecanemab), an approved anti-amyloid Alzheimer's therapy, making it the most direct large-pharma competitor for HMTM in the same disease.
• Biogen: Global neurology-focused biopharma co-marketing Leqembi and previously launching Aduhelm, representing the established Alzheimer's commercial competitor with deep payer and prescriber relationships.

Emerging players

• Denali Therapeutics: Clinical-stage biopharma developing therapeutics for neurodegenerative diseases with an emphasis on biological targets and CNS delivery, comparable in neurodegeneration focus and platform-style pipeline approach.
• BioVie: Clinical-stage biopharma developing therapies for Alzheimer's disease and other neurological conditions, comparable in late-stage CNS pipeline and pre-commercial regulatory positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/taurx-therapeutics
• Xx.com/TauRx
• Facebookfacebook.com/44017048267

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TauRx Pharmaceuticals